title: Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications.
abstract: BACKGROUND
  Optimal immunosuppression is essential to maintain kidney allograft viability but minimizing toxicity is also fundamental.
  
  
  OBJECTIVE
  This article compares immunosuppressants, corticosteroids, cyclosporine, tacrolimus, and basiliximab, which are used in the treatment regimens for renal transplantation. The analyses evaluated their effectiveness to prevent acute rejection episodes and to reduce the appearance of other complications, mainly infectious disease complications.
  
  
  METHODS
  Ninety-five patients were analysed during the first year after primary renal transplantation. These patients were included in a random way in 3 different groups according to the immunosuppressant drug therapy: Group I (35 patients) received corticosteroids + CsA; Group II (35 patients) received corticosteroids + CsA + Basiliximab; Group III (25 patients) received corticosteroids + Tacrolimus + Basiliximab.
  
  
  RESULTS
  Among the 95 patients, 9 presented with an acute rejection episode in Group I. None in Group II, and one in group III. With reference to the infectious disease complications, the incidence of oral herpes was one case in Group I, 4 cases in Group II, and 2 cases in group III.
  
  
  CONCLUSIONS
  Treatment with Basiliximab produced a significantly lower incidence of acute rejection cases and an increase in infectious disease complications, such as lip herpes.
authors.affiliation: Nephrology Department, University Hospital, Valladolid, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Martin Garcia
authors.forename: J
authors.initials: J
authors.lastname: Martin Gago
authors.forename: A
authors.initials: A
authors.lastname: Mendiluce
authors.forename: R
authors.initials: R
authors.lastname: Gordillo
authors.forename: J
authors.initials: J
authors.lastname: Bustamente
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology*; D006560:Herpes Labialis / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology*; D011993:Recombinant Fusion Proteins; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D016559:Tacrolimus